82 results about "Gastro-esophageal reflux disease" patented technology

The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

GERD is treated through a method and apparatus of stimulating the body organ to accelerate a discharge of contents from the duodenum of the patient to thereby encourage discharge of contents from the stomach of the patient across the pyloric valve and into the duodenum.

The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions.

The present invention provides compositions for treatment of gastro-esophageal reflux disorders. The compositions include at least two of the following: (i) one or more digestive enzymes; (ii) one or more probiotics; and (iii) stevia. Also provided are processes for preparing the compositions useful for treatment of gastro-esophageal reflux disorders, and methods of treating subjects against gastro-esophageal reflux disorders, which include administering to a subject a therapeutically effective amount of the compositions of the present invention.

Systems, apparatus, and methods for the treatment of obesity and/or gastro-esophageal reflux disease (GERD). An embodiment includes an implantable device having an adjustable curved portion configured for exerting a suitable mechanical force on one or more tissues or organs targeted for treatment. Embodiments of the device neuromodulate nerve tissue to effect treatment of obesity and/or GERD. Another embodiment includes an intraluminal guide for guiding placement of the implantable device in the patient.

Stabilized substituted benzimidazole modified release pharmaceutical formulations with at least two drug-containing fractions, wherein the release from a first fraction precedes the release from a second fraction, pharmaceutical excipients, processes for preparing the stable formulations, packaging therefor, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

Devices, systems, and methods for treating gastro-esophageal reflux disease (GERD) include anti-reflux valves and retainers for securing them within the lumen of the esophagus, stomach, or a hiatal hernia. The retainers contain inflatable balloons, some of which may be enveloped by a flexible shell that is used to secure the balloon to tissue. Devices with more than one balloon, a low-profile leaf valve, and a sleeve valve are used to treat reflux in patients with a hiatal hernia. The leaf valve may also be configured for its control by constriction by gastrointestinal lumen muscle, through radial compression of the valve's flange. Bi-directional combination valves are used to treat or diagnose patients with reflux due to transient lower esophageal sphincter relaxations (TLESR). Those valves pass reflux through a channel in which gas and liquid reflux are separated. Methods are described for treating GERD patients who (1) have no hiatal hernia, (2) have a hiatal hernia that is fixed in place, or (3) have a hiatal hernia that slides above and below the diaphragm. Methods are also described for delivering GERD-treatment devices to their target locations within the patient's gastrointestinal tract.

Disclosed is an expandable percutaneous sheath, for introduction into the body while in a first, low cross-sectional area configuration, and subsequent expansion of at least a part of the distal end of the sheath to a second, enlarged cross-sectional configuration. The sheath is configured for use in the upper gastrointestinal tract and has utility in the performance of procedures in the esophagus and stomach. The access route is through the anterior abdominal wall to the stomach. The distal end of the sheath is maintained in the first, low cross-sectional configuration during advancement through the abdominal wall and into the stomach. The distal end of the sheath is subsequently expanded using a radial dilatation device. In an exemplary application, the sheath is utilized to provide access for a diagnostic or therapeutic procedure such as diagnosis and repair of gastro esophageal reflux disease. The sheath further can be secured within the gastrointestinal system and be used to draw the stomach wall against the abdominal wall.

Devices, systems, and methods for treating gastro-esophageal reflux disease (GERD) include anti-reflux valves and retainers for securing them within the lumen of the esophagus, stomach, or a hiatal hernia. The retainers contain inflatable balloons, some of which may be enveloped by a flexible shell that is used to secure the balloon to tissue. Methods are described for treating GERD patients who (1) have no hiatal hernia, (2) have a hiatal hernia that is fixed in place, or (3) have a hiatal hernia that slides above and below the diaphragm. Methods are also described for delivering GERD-treatment devices to their target locations within the patient's gastrointestinal tract.

A fiber optical device suitable for treating a wide variety of medical conditions that involve shrinking or tightening of cartilaginous tissue, connective tissue, or muscle tissue comprises an optical fiber capable of laser energy delivery to a predetermined tissue site along with a biocompatible cooling fluid. Illustrative treatable medical conditions are female and male unitary incontinence, female stress urinary incontinence, gastro esophageal reflux disease, obesity, Type 2 diabetes, fecal incontinence, and the like. A preferred laser energy source is a CTH:YAG laser.

The invention provides a combined drug of pantoprazole and domperidone and in particular provides application of pantoprazole and domperidone to preparing combined injections for treating gastric ulcer, duodenal ulcer, gastro-esophageal reflux diseases or functional dyspepsia. The invention also provides the combined injections for treating gastric ulcer, duodenal ulcer, gastro-esophageal reflux diseases or functional dyspepsia, including different specifications of unit preparations, pantoprazole and domperidone for simultaneous, respective or successive administration and preparations prepared by pharmaceutically acceptable vectors. The weight ratio of pantoprazole and domperidone is 1:1-5:1, and the pantoprazole and domperidone contain excipients, stabilizing agents, etc. Through combined injection administration, the invention improves the bioavailability of pantoprazole and domperidone and ensures the treatment effects to be obviously better.

The invention provides a medicine for treating gastroesophageal reflux disease. The medicine is characterized by being prepared from the following medicine materials by weight: 6-12 parts of folium eriobotryae, 0.5-2 parts of platycodon grandiflorum and 6-12 parts of largehead atractylodes rhizome. The invention also provides the application of the medicine in drugs for treating gastroesophageal reflux disease, reflux esophagitis and non-erosive gastroesophageal reflux disease. The medicine for treating gastroesophageal reflux disease has the advantages that the clinical symptoms can be remarkably relieved when the medicine is used for treating the gastroesophageal reflux disease, symptoms of heartburn, acid regurgitation, anabole, causalgia post sternum, pharyngeal discomfort, belching, epigastric distention, epigastric pain are significantly improved, and the general curative effect of the medicine is similar to that of common clinically used acid-suppressive drug omeprazole and is similar to that of traditional Chinese medicine compositions disclosed in comparison files, but the medicine provided by the invention has advantages in improving individual symptoms; the medicine provided by the invention prepared from pure traditional Chinese medicine materials, has no toxic and side effects, and can be easily accepted by patients; the material components are less, the materials are abundant and low in price and are easily obtained, and the preparation process is simple and is suitable for being widely generalized and used.